A meta-analysis of four randomized placebo-controlled trials (REFLEX, SERENE, DANCER, and IMAGE) revealed that RTX provides additional therapeutic benefits in seropositive RA, particularly in patients who have not responded to at least one TNF inhibitor [135]. The gene discussed is TNF; the disease is rheumatoid arthritis.